Spero Therapeutics, Inc. (SPRO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 11.93 |
| Open | 11.91 |
| Bid | 11.89 x 900 |
| Ask | 19.00 x 800 |
| Day's range | 11.69 - 13.35 |
| 52-week range | 11.69 - 22.24 |
| Volume | |
| Avg. volume | 106,069 |
| Market cap | 426.672M |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Spero (SPRO) Application for UTI Drug Gets Priority Review
Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.
- Simply Wall St.
What Type Of Shareholders Make Up Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Registry?
Every investor in Spero Therapeutics, Inc. ( NASDAQ:SPRO ) should be aware of the most powerful shareholder groups...
- Zacks
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
